Holen Sie sich die Stockscreener-App
31.28
6.87%
2.01
Schlusskurs vom Vortag:
$29.27
Offen:
$29.09
24-Stunden-Volumen:
86,555
Relative Volume:
1.84
Marktkapitalisierung:
$664.51M
Einnahmen:
$54,000
Nettoeinkommen (Verlust:
$-210.26M
KGV:
-39.59
EPS:
-0.79
Netto-Cashflow:
$-159.01M
1W Leistung:
+40.21%
1M Leistung:
+76.92%
6M Leistung:
+189.63%
1J Leistung:
+70.89%
1-Tages-Spanne:
$29.00
$32.80
1-Wochen-Bereich:
$21.39
$32.80
52-Wochen-Spanne:
$7.65
$32.80
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Firmenname
Lyell Immunopharma Inc
Sektor
Branche
Telefon
650 695-0677
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Vergleichen Sie LYEL mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
31.28 | 621.81M | 54,000 | -210.26M | -159.01M | -0.79 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-30 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-06-27 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-11-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | BofA Securities | Buy |
| 2021-07-12 | Eingeleitet | Goldman | Buy |
| 2021-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-12 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Lyell Immunopharma Inc Aktie (LYEL) Neueste Nachrichten
Lyell Immunopharma Shares Rise After HC Wainwright Upgrade - marketscreener.com
H.C. Wainwright upgrades Lyell to 'buy' on cell therapy progression - TradingView
This Eaton Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday - Benzinga
Century Therapeutics Appoints Accomplished Biotechnology Leaders Dr. Han Lee and Dr. Martin Murphy to Board of Directors - GlobeNewswire Inc.
LYEL Analyst Rating Upgrade: HC Wainwright & Co. Sets New Price Target | LYEL Stock News - GuruFocus
HC Wainwright & Co. Upgrades Lyell Immunopharma (LYEL) - Nasdaq
Lyell Immunopharma climbs after reporting strong CAR T-cell therapy results - MSN
Lyell Immunopharma stock rises on strong cancer therapy trial data By Investing.com - Investing.com Canada
Lyell Immunopharma stock rises on strong cancer therapy trial data - Investing.com
Lyell Immunopharma Presents Promising CAR T-Cell Data - TipRanks
Lyell Immunopharma (Nasdaq: LYEL) posts 76% complete responses with ronde-cel in LBCL - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Sets New 12-Month High – Here’s What Happened - Defense World
Lyell Immunopharma Modernizes Bylaws for Shareholder Engagement - TipRanks
Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 11.6%Should You Buy? - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Sets New 12-Month HighTime to Buy? - MarketBeat
Will Lyell Immunopharma Inc. stock sustain high P E ratiosTrade Signal Summary & Growth Oriented Trading Recommendations - Newser
Decheng Capital LLC Sells 11,313,875 Shares of Lyell Immunopharma, Inc. $LYEL - MarketBeat
ASH 2025 Roundup: Companies With Key Data Presentations - RTTNews
What analysts say about Lyell Immunopharma Inc stockInsider Trading Compliance & Individual Stock Tracking Service - earlytimes.in
What drives Lyell Immunopharma Inc stock priceHigh Beta Stocks & Free High Yield Growth Strategies - earlytimes.in
Lyell Immunopharma (NASDAQ:LYEL) Hits New 52-Week HighHere's What Happened - MarketBeat
Published on: 2025-11-26 22:33:12 - BỘ NỘI VỤ
Foresite Capital Management IV LLC Sells 15,207,600 Shares of Lyell Immunopharma, Inc. $LYEL - MarketBeat
Lyell Immunopharma (LYEL) Sees Price Target Doubling by HC Wainw - GuruFocus
ETFs Investing in Lyell Immunopharma, Inc. Stocks - TradingView
Lyell Immunopharma, Inc.'s (NASDAQ:LYEL) one-year returns climbed after last week's 13% gain, institutional investors must be happy - simplywall.st
Is Lyell Immunopharma Inc. stock trading at a premium valuationJuly 2025 Trends & AI Powered Trade Plan Recommendations - newser.com
How Lyell Immunopharma Inc. stock performs in rate cut cyclesJuly 2025 Momentum & Technical Pattern Based Signals - newser.com
Will Lyell Immunopharma Inc. stock pay special dividendsJuly 2025 Institutional & Accurate Technical Buy Alerts - newser.com
Real time social sentiment graph for Lyell Immunopharma Inc.Weekly Profit Report & Reliable Volume Spike Trade Alerts - newser.com
Will Lyell Immunopharma Inc. benefit from macro trendsQuarterly Portfolio Review & Fast Exit and Entry Trade Guides - newser.com
How Lyell Immunopharma Inc. stock performs in weak economyTrade Exit Summary & Real-Time Stock Entry Alerts - newser.com
Is it too late to sell Lyell Immunopharma Inc.Weekly Investment Recap & Daily Stock Momentum Reports - newser.com
Is Lyell Immunopharma Inc. stock attractive for retirement portfoliosLayoff News & Safe Entry Point Alerts - newser.com
Lyell Immunopharma Secures Global Rights to CAR T-Cell Candidate for Metastatic Colorectal Cancer - Global Legal Chronicle
Strategies to average down on Lyell Immunopharma Inc.July 2025 Institutional & Smart Investment Allocation Tips - newser.com
Published on: 2025-11-16 00:33:42 - newser.com
Is Lyell Immunopharma Inc. still worth holding after the dipSwing Trade & Reliable Volume Spike Trade Alerts - newser.com
Lyell Immunopharma acquires exclusive global rights to LYL273 - MSN
Lyell Immunopharma CSO sells $2230 in shares By Investing.com - Investing.com Nigeria
Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):